Erratum to: Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen (Journal of Neuro-Oncology DOI: 10.1007/s11060-010-0444-x));Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen

Journal of Neuro-Oncology

Volumn 103, Issue 3, 2011, Pages 673-680

  Parekh, Chintan ^a   Jubran, Rima ^a   Erdreich Epstein, Anat ^a   Panigrahy, Ashok ^a   Bluml, Stefan ^a   Finlay, Jonathan ^a   Dhall, Girish ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Bevacizumab; Children; Gliomas; Imaging

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CYCLOPHOSPHAMIDE; ETOPOSIDE; IRINOTECAN; LOMUSTINE; TEMOZOLOMIDE; THALIDOMIDE; THIOTEPA; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN SURGERY; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GLIOMA; HUMAN; HYPERTENSION; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTOPENIA; TUMOR BLEEDING; VOMITING;

EID: 79959781204     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0475-3     Document Type: Erratum

References (32)

1. Broniscer A (2006) Past, present, and future strategies in the treatment of high-grade glioma in children. Cancer Invest 24(1):77-81
2. CBTRUS (2008) Statistical report: Primary brain tumors in the united states, 2000-2004. Published by the central brain tumor registry of the United States
3. Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, Evans AE, Wara W, Hammond D (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the childrens cancer study group. J Neurooncol 7(2):165-177 (Pubitemid 19182070)
4. Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M et al (1995) Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens cancer group. J Clin Oncol 13(1):112-123
5. Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. The oncologist 9(2):197-206 (Pubitemid 38452119)
6. Huncharek M, Wheeler L, McGarry R, Geschwind JF (1999) Chemotherapy response rates in recurrent/progressive pediatric glioma; results of a systematic review. Anticancer Res 19(4C):3569-3574 (Pubitemid 30000222)
7. Gottardo NG, Gajjar A (2008) Chemotherapy for malignant brain tumors of childhood. J Child Neurol 23(10):1149-1159
8. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal brain tumor group. J Clin Oncol 17(9):2762-2771 (Pubitemid 29415233)
9. Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom children's cancer study group and French society for pediatric oncology intergroup study. J Clin Oncol 20(24):4684-4691
10. Ruggiero A, Cefalo G, Garre ML, Massimino M, Colosimo C, Attina G, Lazzareschi I, Maurizi P, Ridola V, Mazzarella G, Caldarelli M, Di Rocco C, Madon E, Abate ME, Clerico A, Sandri A, Riccardi R (2006) Phase ii trial of temozolomide in children with recurrent high-grade glioma. J Neurooncol 77(1):89-94 (Pubitemid 43870566)
11. Kerbel RS (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312(5777):1171-1175
12. Vredenburgh JJ, Desjardins A, Herndon JE II, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253-1259 (Pubitemid 46424067)
13. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE (2010) Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 28(18):3069-3075
14. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280 (Pubitemid 20195640)
15. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779-787
16. Finlay J, Tang R, Haley K, Gardner S, Allen J, Butturini A, Puccetti D, Cornelius A, Torkildson J, Ji L, Sposto R (2007) The treatment of young children with malignant gliomas and diffuse intrinsic pontine gliomas (DIPG): results of an irradiationavoiding strategy, the "Head Start" protocols. Oral presentation, 12th Scientific Meeting of the Society of Neuro-oncology, Dallas, Texas, November 2007. Neuro-oncology 9(4):539
17. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427-434 (Pubitemid 36910021)
18. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A (2005) Phase i/ii trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the her-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(11):2544-2555
19. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17(6):1815-1824 (Pubitemid 29269252)
20. Raffel C, Frederick L, O'Fallon JR, Atherton-Skaff P, Perry A, Jenkins RB, James CD (1999) Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with pten mutations. Clin Cancer Res 5(12):4085-4090 (Pubitemid 30013789)
21. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW (2000) Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain pathol Zurich, Switzerland 10(2):249-259 (Pubitemid 30181093)
22. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN (1996) Cdkn2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56(1):150-153 (Pubitemid 26010393)
23. Szybka M, Bartkowiak J, Zakrzewski K, Polis L, Liberski P, Kordek R (2003) Microsatellite instability and expression of DNA mismatch repair genes in malignant astrocytic tumors from adult and pediatric patients. Clin Neuropathol 22(4): 180-186 (Pubitemid 36869992)
24. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the children's oncology group. Cancer 110(7):1542-1550 (Pubitemid 47463069)
25. Pronin IN, Holodny AI, Petraikin AV (1997) MRI of high-grade glial tumors: correlation between the degree of contrast enhancement and the volume of surrounding edema. Neuroradiology 39(5):348-350 (Pubitemid 27216168)
26. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61(18):6624-6628 (Pubitemid 32896475)
27. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93(25):14765-14770 (Pubitemid 26419043)
28. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G (2008) HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13(3):206-220 (Pubitemid 351318372)
29. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ (2008) Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children's oncology group study. J Clin Oncol 26(3):399-405 (Pubitemid 351171691)
30. Bomgaars L, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM (2006) A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer 46(1):50-55 (Pubitemid 41779317)
31. Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM (2006) Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 24(4):563-570 (Pubitemid 46630418)
32. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crino L, Ermani M (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (gicno). Br J Cancer 95(9):1155-1160 (Pubitemid 44658477)